ReviewExperimental physiology2026
Leptin-cholesterol crosstalk in pregnancy: Mechanistic implications for placental function and cardiometabolic programming.
Review in Experimental physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Leptin-cholesterol crosstalk in pregnancy: Mechanistic implications for placental function and cardiometabolic programming.Experimental physiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pregnancy requires the coordinated maternal reorganization of lipid and endocrine pathways to sustain fetal growth and anticipate neonatal nutrition. Leptin, produced by adipose tissue and the placenta, acts as an integrative signal linking maternal energy status with trophoblast function and vascular adaptation, while cholesterol provides essential structural and hormonal substrates required for steroidogenesis and neurodevelopment. Emerging evidence indicates that leptin and cholesterol act as convergent regulators of metabolic and cardiovascular (CV) adaptation during pregnancy. We propose that excessive hyperleptinaemia and maternal hypercholesterolaemia, frequently coexisting, form a convergent axis that modulates placental signalling, alters the epigenetic regulation of lipid transporters and disrupts mitochondrial homeostasis. Mechanistically, this convergence operates through hepatic, epigenetic and renal pathways detailed throughout this review. Beyond the placenta, dysregulation of the leptin-cholesterol axis may extend to maternal organs central to CV homeostasis, particularly the kidney. Emerging evidence suggests that similar leptin-driven renal pathways may operate during pregnancy, amplifying vascular dysfunction and susceptibility to hypertensive complications. This perspective highlights the leptin-cholesterol axis as a mechanistic link connecting placental, kidney and CV pathways within the Developmental Origins of Health and Disease (DOHaD) paradigm, with potential implications for long-term cardiometabolic risk. This review integrates molecular, epigenetic and clinical evidence to emphasize lipoprotein-centred mechanisms, identify critical knowledge gaps and discuss translational opportunities for nutritional intervention, biomarker development and early-life preventive strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.